Vivoryon Therapeutics N.V. announced that it has completed the parallel group, dose-finding part of its European Phase 2b study VIVIAD (NCT04498650) and that the independent Data Safety Monitoring Board (DSMB) has selected the higher dose investigated, 600 mg twice daily (BID), as the final dose to be administered in the second part of the study. VIVIAD is a Phase 2b study designed to evaluate the safety, tolerability and efficacy of varoglutamstat in 250 subjects with mild cognitive impairment (MCI) and mild Alzheimer's disease (AD). The DSMB decision is based on safety data from 181 patients, 90 of which had completed the week 24 treatment visit at the May 17 cut-off date.

All subjects randomized to the treatment arm will be treated at the selected dose of 600 mg BID moving forward and will continue treatment for up to 48-96 weeks dependent on study entry date. VIVIAD is actively enrolling patients and will continue to evaluate its primary and secondary outcome measures, which include multiple cognitive, safety and biomarker endpoints. Vivoryon remains on target to report final data for the study in the second half of 2023.